Decision analysis for the cost effectiveness of sestamibi scintimammography in minimizing unnecessary biopsies

Quarterly Journal of Nuclear Medicine

Volumn 44, Issue 2, 2000, Pages 168-185

  Allen, M W ^a   Hendi, P ^a   Schwimmer, J ^a   Bassett, L ^a   Gambhir, S S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast neoplasms radionuclide imaging; Cost benefit analysis; Health care costs; Mammography; Technetium 99mTC sestamibi diagnostic use

Indexed keywords

ARTICLE; BREAST BIOPSY; BREAST CANCER; COST EFFECTIVENESS ANALYSIS; DECISION THEORY; HEALTH CARE COST; HUMAN; LIFE EXPECTANCY; MAMMOGRAPHY; SCINTIMAMMOGRAPHY; UTILIZATION REVIEW;

BIOPSY; BREAST NEOPLASMS; COST SAVINGS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DECISION SUPPORT TECHNIQUES; DECISION TREES; DISEASE PROGRESSION; FEMALE; HEALTH CARE COSTS; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; LIFE EXPECTANCY; MAMMOGRAPHY; MASS SCREENING; MEDICARE; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M SESTAMIBI; UNITED STATES; UNNECESSARY PROCEDURES;

EID: 0033898447     PISSN: 11243937     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (89)

1. Cancer statistics, 1995
2. The lifetime risk developing breast cancer
3. Review of imaging techniques for the diagnosis of breast cancer: A new role of prone scintimammography using technetium-99m sestamibi
4. Breast cancer screening for elderly women with and without comobrid conditions. A decision analysis model
5. The value of mammography screening in women under 50 years of age
6. Cost-effectiveness of breast cancer screening: Preliminary results of a systematic review of the literature
7. Screening mammography in women aged 40-49 years: Analysis of cost-effectiveness
8. Benefits and costs of screening and treatment for early breast cancer. Development of a basic benefit package
9. The prevalence of carcinoma in palpable vs impalpable, mammographically detected lesions
10. The role of Technetium-99m-labeled sestamibi scintimammography in diagnosis of breast cancer
11. Scintimammography: Magic bullet or false promise?
12. Technetium-99m-sestamibi imaging in breast cancer: An alternative to thallium-201 imaging
13. Technetium-99m-methylene diphosphonate scintimammography to image primary breast cancer
14. A study on the cost effectiveness of sestamibi scintimammography for screening women with dense breast for beast cancer
15. Decision analysis: MIBI imaging of nonpalpable breast abnormalities
16. Optimization of X-ray mammography and technetium-99m methoxyisobutylisonitrile cintimammography in the diagnosis of non-palpable breast lesions
17. 99mTc-MIBI scintimammography in suspected breast cancer
18. Sesitivity analysis in the cost-effectiveness of breast cancer screening
19. The palpable breast nodule. A cost-effectiveness analysis of alternate diagnostic approaches
20. Methods of cost-effectiveness analysis: Areas of consensus and debate
21. Analysing clinical decision analyses
22. Symbolic interactive modeling package and learning environment (SIMPLE), A new easy method for compartmental modeling
23. MD@: A physician-friendly decision analysis tool
24. Interpreting the mammogram report
25. Update of the swedish two-county program of mammographic screening for breast cancer
26. The DOM project for the early detection of breast cancer, Utrecht, The Netherlands
27. Breast cancer detection demonstration project: Five-year summary report
28. Mammography in symptomatic women 50 years of age and under, and those over 50
29. Triple approach in the diagnosis of dominant breast masses: Combined physical examination, mammography, and fine-needle aspiration
30. The benefits and risks of mammographic screening for breast cancer
31. The abnormal mammogram radiographic findings, diagnostic options, pathology, and stage of cancer diagnosis
32. Management of mammographic indeterminate lesions
33. An analysis of the results of mammographically guided biopsies of the breast
34. Likelihood of malignant disease for various categories of mammographically detected, nonpalpable breast lesions
35. Mammography-guided stereotactic fine-needle aspiration cytology of nonpalpable breast lesions: Prospective comparison with surgical biopsy results
36. Sensitivity and specificity of first screen mammography in the Canadian National Breast Screening Study: A preliminary report from five centers
37. Accuracy of combined clinical-mammographic-cytologic diagnosis of dominant breast masses. A prospective study
38. Five-year experience with single-view mammography randomized controlled screening in Sweden
39. Medical audit of a rapid-throughput mammography screening practice: Methodology and results of 27,114 examinations
40. The New Mexico Mammography Project. Screening mammography performance in Albuquerque, New Mexico, 1991 to 1993
41. A prospective study of the value of core needle biopsy and fine needle aspiration in the diagnosis of soft tissue masses
42. Nonpalpable breast lesions: Findings of stereotaxic needle-core biopsy and fine-needle aspiration cytlogy
43. Stereotaxic core biopsy of breast lesions
44. Nonpalpable breast lesions: Corelation of stereotaxic large-core needle biopsy and surgical biopsy results
45. Breast biopsy: A comparative study of stereotaxically guided core and excisional techniques
46. Stereotactic needle biopsy for occult breast lesions: A minimally invasive alternative
47. Fine needle aspiration cytology, imprint cytology and tru-cut needle biopsy in breast lumps: A comparative evaluation
48. Imaging-guided core biopsy of the breast
49. TRU-CUT needle niopsy of the breast. An analysis of its specificity and sensitivity
50. US-guided automated large-core breast biopsy
51. Percutaneous large-core breast biopsy: A multi-institutional study
52. Ultrasonographically guided fine needle aspiration cytology and core-needle biopsy in the dianosis of breast tumors
53. Core biopsy of breast lesions
54. Core needle aspiration biopsy of palpable breast masses
55. Prone scintimammography in patients with suspicion of carcinoma of the breast
56. Technetium-99m-MIBI scintimammography for suspicious breast lesions
57. Technetium-99m-sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement
58. Mammoscintigraphy with Technetium-99m-sestamibi in suspected breast cancer
59. 99mTC-sestamibi in the diagnosis of breast cancer. Report on 100 cases
60. 99mTC-MIBI scintimammography in 300 consecutive patients: Factors that may affect accuracy
61. Technitium-99m sestamibi scintimammography: The influence of histopathological characteristics, lesion size and the presence of carcinoma in situ in the detection breast carcinoma
62. Can reduced imaging times be used for scintimammography?
63. 99mTC-sestamibi scintigraphy, mammography, and fine-needle aspiration cytology: Comparative study in 64 surgically treated patients
64. 99mTc-MIBI scintimammography for the detection of breast maligancies: The contribution of the count ratio to specificity
65. 99mTc-sestamibi
66. 99mTc-MIBI scintimammography iin the evaluation of breast lesions and axillary involvement: A comparison with mammography and histopathological diagnosis
67. Double-phase 99mTc-sestamibi scintimammography and trans-scan in diagnosing breast cancer
68. Scintimmamographic analysis of nonpalpable breast lesions previously identified by conventional mammography
69. Can scintimammography reduce 'unnecessary' biopsies?
70. Technetium-99m-sestamibi scintimammography for the detection of breast carcinoma: Comparison between planar and SPECT imaging
71. 99mTc sestamibi breast imaging: Multicenter trial results
72. Estimation of radiation risk from screening mammography: Recent trends and comparison with expected benefits
73. The epidemiology of mass breast cancer screening - A plea for a valid measure of benefit
74. The saferty and versatility of video-thoracoscopy: A prospective analysis of 895 consecutive cases
75. A convenient approximation of life expectancy (the 'DEALE'). I. Validation of the method
76. A convenient approximation of life expectancy (the 'DEALE'). II. Use in medical decision-making
77. Staging of cancer of the colon and rectum
78. The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women
79. Review of stereotaxic large-core needle biopsy and surgical biopsy results in nonpalpable breast lesions
80. Mammographically guided fine-needle aspiration biopsy of non-palpable breast lesions. Can it replace open biopsy?
81. Stereotaxis needle-core biopsy and fine-needle aspiration cytologic evaluation of nonpalpable breast lesions
82. Role of fine-needle aspiration cytology and needle-core biopsy in the diagnosis of lobular carcinoma of the breast